Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples